pdf

O’Melveny’s Scrivano Quoted in Forbes Regarding Firm’s Representation of BGI In Acquisition

September 13, 2013

O’Melveny’s representation of BGI Shenzhen, China’s largest biotech company, in its acquisition of Complete Genomics earlier this year received coverage in a September 13, 2013, Forbes article, titled, “How China’s Biggest Biotech Company Cracked The U.S. Market.”  According to the article, with this move, BGI acquired “the know-how to make the machines that process the data and a foothold in the U.S. sequencing service market, enabling it to serve locals directly.”  O’Melveny partner Paul Scrivano, who advised BGI in the acquisition, told the publication that “unlike other controversial Chinese acquisitions in the U.S. made by state-owned companies,” BGI is funded by private investors.  With this acquisition, BGI not only increases their pace of entering the U.S. market but also increases their competitive standing, according to the article.

Scrivano is co-head of O’Melveny’s Mergers and Acquisitions Practice in the US.  He divides his time between the Firm’s New York, San Francisco, and Silicon Valley offices.